Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
1/18/2013 9:16:36 AM
More...
|
Callisto Pharmaceuticals Stockholders Approve Merger With Synergy Pharmaceuticals
1/15/2013 9:19:08 AM
More...
|
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals
7/23/2012 9:50:56 AM
More...
|
Callisto Pharmaceuticals Adjourns Annual Stockholders Meeting Due to Lack of a Quorum
7/12/2010 9:32:21 AM
More...
|
Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis
1/27/2009 9:52:31 AM
More...
|
Callisto Pharmaceuticals’ Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers
12/9/2008 1:23:38 PM
More...
|
Callisto Pharmaceuticals Announces $3.0 Million Financing by Its Synergy Pharmaceuticals Subsidiary and Related Transactions Leaving Callisto with a 68% Stake in Synergy
7/21/2008 11:08:20 AM
More...
|
Callisto Pharmaceuticals Opens Phase I Clinical Trial of SP-304 to Treat Chronic Constipation and Irritable Bowel Syndrome
6/4/2008 10:12:57 AM
More...
|
Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced Carcinoid Cancer
5/16/2008 8:57:28 AM
More...
|
Callisto Pharmaceuticals Receives Notice of Delisting From AMEX - Subject to Appeal
4/14/2008 9:26:24 AM
More...
|
|